 |
|
p53 Mutation as a Prognostic Marker in Advanced Laryngeal Carcinoma
Carol R. Bradford, MD;
Shaobo Zhu, MD;
Judy Poore, MS;
Susan G. Fisher, PhD;
Theodore F. Beals, MD;
Didier Thoraval, PhD;
Samir M. Hanash, MD, PhD;
Thomas E. Carey, PhD;
Gregory T. Wolf, MD
Arch Otolaryngol Head Neck Surg. 1997;123(6):605-609.
Abstract
| |
Objective
To determine the relationship of p53 mutations in advanced laryngeal carcinomas to p53 immunohistochemistry, organ preservation, and patient survival.
Design
Paraffin-embedded tumor specimens were obtained from patients enrolled in the Department of Veterans Affairs Laryngeal Cancer Cooperative Study, a multi-institutional randomized clinical trial comparing induction chemotherapy (cisplatin and fluorouracil) plus radiation therapy with surgery plus postoperative radiation therapy. Tumor specimens were analyzed for p53 mutations in exons 5 through 8 by using single-strand conformational polymorphism (SSCP) analysis followed by DNA sequencing of all variants. Fiveyear follow-up data were available for all patients studied.
Subjects
Forty-four patients enrolled in the Department of Veterans Affairs Laryngeal Cancer Cooperative Study from whom paraffin-embedded tumor specimens were readily available.
Results
p53 immunostaining did not correlate with p53 SSCP and DNA sequencing results. More than half (62% [16/26]) of the tumors that overexpressed p53 immunohistochemically did not have a detectable p53 gene mutation. Similarly, 39% (7/18) of tumors that did not overexpress p53 did have a p53 gene mutation. p53 mutations were present in 39% of tumors tested. Mutations within exon 5 made up 41% of p53 gene mutations in laryngeal carcinomas. Transitions were the most common type of mutation in this study (92% of mutations).
Conclusions
The presence of a p53 mutation as detected by SSCP is associated with decreased patient survival. Further study is required to confirm this relationship and to determine whether specific p53 mutations predict organ preservation.
Arch Otolaryngol Head Neck Surg. 1997;123:605-609
Author Affiliations
for the Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group
From the Departments of Otolaryngology/Head and Neck Surgery (Drs Bradford, Zhu, Carey, and Wolf and Ms Poore), Pathology (Dr Beals), and Pediatrics and Communicable Diseases (Drs Thoraval and Hanash), University of Michigan Medical Center, Ann Arbor; the Department of Veteran Affairs Medical Center, Ann Arbor (Drs Bradford, Zhu, and Beals and Ms Poore); and the Department of Obstetrics and Gynecology, Loyola University, Maywood, Ill (Dr Fisher). A list of participants in the Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group appears in the acknowledgment section at the end of the article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer
Kumar et al.
JCO 2008;26:3128-3137.
ABSTRACT
| FULL TEXT
Individualized Treatment Selection in Patients With Head and Neck Cancer: Do Molecular Markers Meet the Challenge?
Singh and Pfister
JCO 2008;26:3114-3116.
FULL TEXT
Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer
Kumar et al.
Arch Otolaryngol Head Neck Surg 2008;134:363-369.
ABSTRACT
| FULL TEXT
Reduced Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines Correlates with Mutations Affecting the COOH-Terminal Nuclear Localization Signal of p53
Mandic et al.
Clin. Cancer Res. 2005;11:6845-6852.
ABSTRACT
| FULL TEXT
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL
Bauer et al.
Molecular Cancer Therapeutics 2005;4:1096-1104.
ABSTRACT
| FULL TEXT
p16 and p53 Protein Expression as Prognostic Indicators of Survival and Disease Recurrence from Head and Neck Cancer
Geisler et al.
Clin. Cancer Res. 2002;8:3445-3453.
ABSTRACT
| FULL TEXT
Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent
Osman et al.
JCO 2002;20:2980-2987.
ABSTRACT
| FULL TEXT
Frequencies of Tetramer+ T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in the Circulation of Patients with Head and Neck Cancer
Hoffmann et al.
Cancer Res. 2002;62:3521-3529.
ABSTRACT
| FULL TEXT
Cyclin D1 and p53 Overexpression Predicts Multiple Primary Malignant Neoplasms of the Hypopharynx and Esophagus
Kohmura et al.
Arch Otolaryngol Head Neck Surg 1999;125:1351-1354.
ABSTRACT
| FULL TEXT
|
